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ABSTRACT
Chronic obstructive pulmonary disease (COPD) is a debilitating condition characterized by
airﬂow limitation that is not fully reversible. It is a major cause of morbidity and mortality and
represents substantial economic and social burden throughout the world. A range of interven-
tions has been developed that decrease symptoms and address complications associated with
COPD. However, to date few interventions have been unequivocally demonstrated to modify
disease progression. Assessment of the potential for interventions to modify disease progres-
sion is complicated by the lack of a clear deﬁnition of disease modiﬁcation and disagreement
over appropriate markers by which modiﬁcation should be evaluated. To clarify these issues, a
working group of physicians and scientists from the USA, Canada and Europe was convened.
The proposed working deﬁnition of disease modiﬁcation resulting from the group discussions
was “an improvement in, or stabilization of, structural or functional parameters as a result of
reduction in the rate of progression of these parameters which occurs whilst an intervention
is applied and may persist even if the intervention is withdrawn”. According to this deﬁnition,
pharmacologic interventions may be considered disease-modifying if they provide consistent
and sustained improvements in structural and functional parameters. Smoking cessation and
lung volume reduction surgery would both qualify as disease-modifying interventions.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a pre-
ventable and treatable disease characterized by airﬂow limita-
tion that is not fully reversible. It is currently the fourth-leading
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cause of death in the world, and both the worldwide prevalence
and mortality associated with COPD are anticipated to increase
in the coming decades (1).
While current pharmacotherapy decreases symptoms
and addresses complications, no interventions have been
unequivocally demonstrated to modify disease progression.
However, the ability to determine whether a drug modiﬁes dis-
ease progression is complicated by the absence of a clear deﬁni-
tion of disease modiﬁcation and disagreement over appropriate
markers by which modiﬁcation should be evaluated. To address
these issues, a working group of respiratory physicians from the
USA and Europe was convened to discuss the evolving con-
cept of disease modiﬁcation in COPD. The list of participants
is presented in the acknowledgements. This review publication
reﬂects the opinions of the two authors, but may not necessarily
reﬂect those of the wider group.
WHAT IS DISEASE PROGRESSION AND
MODIFICATION IN COPD?
No agreed deﬁnition of disease modiﬁcation in COPD cur-
rentlyexists.Onegenericdictionarydeﬁnitionincludes“. . . any
COPD: Journal of Chronic Obstructive Pulmonary Disease June 2009 211Figure 1. Schematic illustration of effects of an intervention on disease progression. Broken lines detail natural progression of a marker of
disease progression; solid lines detail the change in this marker resulting from the intervention. (A) an intervention leading to a sustained change
in the rate of progression that is maintained even after the intervention ceases; (B) an intervention leading to a sustained change in the rate of
progression that occurs only during the time the therapy is administered; (C) an intervention that leads to a sustained improvement in a marker
of disease status but has no effect on the rate of change of that marker over time; (D) an intervention that improves the marker of disease status
during the time it is administered but provides no lasting effect on that marker once it is stopped.
of the changes in a disease state that are caused by an in-
tervention”. This deﬁnition falls short of distinguishing tem-
porary drug effects from those that affect the course of the
disease over time. Broadly speaking a therapeutic intervention
can inﬂuence the course of disease in one of four ways (Fig-
ure 1). An intervention may lead to a sustained change in the
rate of disease progression that is maintained even after the in-
tervention ceases (Figure 1A) or for as long as the therapy is
administered(Figure1B).Alternatively,aninterventionmaynot
affect the rate of disease progression but may lead to sustained
functional/symptomaticimprovement(Figure1C),whicheffec-
tively “turns the clock back” on the disease such that even after
the intervention ceases, function/symptoms remain improved
compared with the time that the intervention was introduced.
Finally, an intervention may simply improve disease status
during the time it is administered (Figure 1D), thus providing
no durable beneﬁt after it is stopped. Consensus in the working
group was that disease modiﬁcation through pharmacotherapy
should be deﬁned only as interventions that alter the rate of
disease progression (Figures 1A and 1B). The concept that in-
terventions that “turned back the clock” should be considered
disease-modifying was viewed as more controversial (Figure
1C). Interventions that only improve the marker of disease sta-
tus during the time they are administered (Figure 1D) were not
considered to be disease-modifying.
Having established what constitutes disease modiﬁcation
through pharmacologic intervention, it was necessary for the
group to identify the most appropriate markers of disease sta-
tus that can be used to monitor this process. A wide range of
outcome measures and markers are available to ascertain the
symptomatic efﬁcacy of pharmacological interventions. The
uses and limitations of these have recently been comprehen-
sively evaluated by the American Thoracic Society/European
Respiratory Society Task force on “Outcomes for COPD phar-
macological trials: from lung function to biomarkers” (2). It
was not the intention of our group to consider the merits and
limitations of measures currently used to establish the symp-
tomatic efﬁcacy of pharmacological interventions, but rather
to determine which of these measures would be appropriate to
establish whether an intervention was modifying the disease
process.
BIOMARKERS FOR DISEASE
PROGRESSION IN COPD
The physiologic hallmark of COPD is expiratory ﬂow limi-
tation and traditionally, disease progression has been measured
by the decline over time in forced expiratory volume in 1 sec-
ond (FEV1). However, in light of a better understanding of the
multidimensional nature of COPD, progression might also be
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Outcome measure Method Potential to measure disease
progression
Practicality
Pathophysiologic
Macrophages, neutrophils,
CD4+ and CD8+
lymphocytes
Bronchoalveolar lavage,
endobronchial biopsy,
transbronchial biopsy
Not yet clear whether this is an
accurate surrogate of disease
progression
Invasive – not practical beyond
small-scale investigation
Airway structural components Transbronchial biopsy Not yet clear whether this is an
accurate surrogate of disease
progression
Invasive – not practical beyond
small-scale investigation
Cytokines, chemokines Induced sputum Little is known concerning
long-term reproducibility and
correlation with disease
progression
Relatively easy and well tolerated but
induction procedure can induce
neutrophilic inﬂammation, and sputum
solubilization may interfere with
radioimmune assays. Samples
predominantly the larger airways and
may not reﬂect inﬂammation of the
small airways
NO, CO, Volatile hydrocarbons
(alkanes, pentanes, ethane)
Exhaled air NO and CO only slightly elevated
in COPD and little known about
correlation with disease
progression
Readily accessible and repeatable but
CO assay is confounded by active and
passive smoking
Ethane correlates with disease
progression
Ethane assay is too complex for routine
use
Oxidative products,
leukotrienes, cytokines, and
pH (which reﬂects tissue
acidiﬁcation due to
inﬂammation)
Exhaled breath
condensate (EBC)
Accuracy of EBC as a valid
reﬂection of alveolar lining ﬂuid
has been questioned
Noninvasive and simple but wide
variability observed due to dilution
from water vapor during condensation
and low concentrations of the
biomarkers
IL-6, IL-8, TNF-α, and CRP Plasma/serum sampling Serum CRP and serum TNF-α do
not correlate with disease
severity. Data on serum IL-6,
IL-8, and ﬁbrinogen are
insufﬁcient and inconclusive
Readily accessible and repeatable
Physiologic
FEV1 Spirometry Worsens over time. Exhibits
sustained improvement with
pharmacologic interventions
Readily accessible and repeatable
Rate of change not easily
altered by pharmacologic
interventions, which may
suggest this measure is
resistant to change or that
pharmacologic approaches
applied to date are ineffective.
Historically considered by many
the paradigm of disease
progression
Patient-centered outcomes
Dyspnea Baseline Dyspnea Index,
Transition Dyspnea
Index
Worsens over time and exhibits
sustained improvement with
pharmacologic and
nonpharmacologic
interventions – could be
considered a surrogate marker
for disease progression
Simple to perform and repeatable, but
standardization of administration in
clinical trials and validity as a measure
of dyspnea has been questioned. The
Transition Dyspnea Index measures
changes in dyspnea from the initial or
baseline state
Exercise capacity 6MWD progressive Worsens over time and exhibits
variable improvement with
pharmacologic and
nonpharmacologic
interventions – could be
considered a surrogate marker
for disease progression
6MWD and progressive cycloergometry
show poor repeatability, learning
effects and effort dependence.
cycloergometry,
constant work
rate submaximal
exercise test
Constant work rate submaximal exercise
test is reliable and repeatable
(Continued on next page)
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Outcome measure Method Potential to measure disease
progression
Practicality
Health-related quality
of life
Disease-speciﬁc questionnaires,
e.g., St George’s Respiratory
Questionnaire
Worsens over time and exhibits variable
improvement with pharmacologic and
nonpharmacologic interventions.
Health status measures reﬂect the
effects of the disease rather than the
disease itself – could be considered a
surrogate marker for disease
progression
Simple to monitor
Exacerbations Patient/physician reports May increase in frequency over time and
exhibit reduced frequency with
pharmacologic interventions; however,
low frequency in mild COPD would
limit utility of this measure at the early
stages of disease
Relatively easy to measure,
although deﬁnitions differ
between clinical trials
Mortality
Mortality rate Physician report Ultimate measure of disease
progression and useful to study
disease modiﬁcation in populations,
but not suitable for monitoring
progression in an individual patient
Complicated by co-morbid
conditions that could contribute
to mortality independently or
additionally, but not exclusively
to COPD
CO, carbon monoxide; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; FEV1, forced expiratory volume in 1 second; IL,
interleukin; 6MWD, 6-minute walking distance; NO, nitric oxide; TNF, tumor necrosis factor.
measured by the rate of change of other outcomes. Surrogate
markers of progression could include those of (a) pathobiology,
(b) physiologic indices, (c) patient-centered outcomes, and, ul-
timately, (d) mortality (Table 1). It is important to note that
interventions that modify disease would be likely to modify the
rate of change of one or more of the markers.
Pathobiology as a surrogate marker for disease
progression in COPD
Since the pioneering work of Hogg and associates (3), the
small airways have been recognized as the major site of airﬂow
limitation in COPD, accounting for up to 90% of the total re-
sistance to ﬂow in the lungs of patients with well-established
disease. Small airway walls contain neutrophils, macrophages,
and both CD4+ and CD8+ T lymphocytes (but not eosinophils)
and their levels progressively increase with disease severity
(Figure 2) (4).
In concert with these inﬂammatory changes, the thickness
of the airway wall structural components (epithelium, lamina
propria, smooth muscle, and adventitia) also increases with dis-
ease severity. These ﬁndings suggest that it may be possible to
track COPD disease progression through serial invasive evalu-
ation of airway histopathology through endobronchial biopsies
(assuming that histopathologic changes in the large airways re-
ﬂect similar changes in the small airways) and transbronchial
biopsies that sample the small airways and distal lung. Disease
progression has been tracked in this way in asthma, but to date,
this has not been performed in COPD (5). While evaluation of
airway changes may be an accurate surrogate of disease pro-
gression in COPD, the invasive techniques required are not
practical or feasible beyond small-scale experimental investiga-
tion. Similar concerns limit the usefulness of bronchoalveolar
lavage.Thus,reliancemustbeplacedonnoninvasivepulmonary
biomarkers.
Induced sputum is a relatively easy and well-tolerated pro-
cedure that can reﬂect inﬂammatory processes in the airway.
Evidence for the utility of this approach in assessing inﬂamma-
tion has been demonstrated by comparing samples taken from
smokers with those from nonsmokers (4, 6). However, induced
sputum also has limitations. For example, (a) it predominantly
samples the larger airways and may not reﬂect inﬂammation of
the small airways; (b) the sputum induction procedure itself can
induce neutrophilic inﬂammation; (c) solubilization of the spu-
tum may interfere with radioimmune assays for the detection of
cytokinesandchemokines;and(d)littleisknownconcerningits
long-term reproducibility or its correlation with COPD severity
and progression.
Exhaled air provides another readily accessible and repeat-
able noninvasive means for monitoring inﬂammation in COPD.
The major exhaled gases that reﬂect lung inﬂammation include
nitric oxide (NO), carbon monoxide (CO), and volatile hydro-
carbons (alkanes, pentanes, ethane), the latter being markers
of lipid peroxidation due to oxidative stress (7). Exhaled NO
levels are commonly elevated in uncontrolled asthma, but are
often normal or only slightly increased in COPD, presumably
due to the conversion of NO into peroxynitrite and nitrate due
to oxidative stress. On the other hand, the alveolar fraction of
exhaled NO (obtained by measuring exhaled NO at different
expiratory ﬂow rates) appears elevated in COPD (8). The rela-
tionship between exhaled NO and COPD severity, progression,
and acute exacerbations, however, remains to be determined.
214 June 2009 COPD: Journal of Chronic Obstructive Pulmonary DiseaseFigure 2. Airway inﬂammatory response, as measured by the percentage of the airways containing polymorphonuclear neutrophils (PMNs),
macrophages, and eosinophils, among patients at each Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage (4). Hogg JC, Chu F,
UtokaparchS,WoodsR,ElliottWM,BuzatuL,CherniackRM,RogersRM,SciurbaFC,CoxsonHO,Par´ ePD.NEnglJMed2004;350:2645–2653.
Copyright c  [2004] Massachusetts Medical Society. All rights reserved.
Exhaled CO (an oxidative breakdown product of heme and thus
amarker ofoxidative stress)iseasilymeasured but maynot bea
useful biomarker as it is only slightly elevated in COPD and its
measurement is confounded by active and passive smoking (9).
Exhaled ethane levels are elevated in COPD and correlate with
disease severity (10); however, the current assay methodology
is too complex for routine assessment.
Exhaled breath condensate is another noninvasive and sim-
ple sampling technique for inﬂammatory mediators in the lung,
including oxidative products, leukotrienes, cytokines, and pH
(which reﬂects tissue acidiﬁcation due to inﬂammation) (6).
Limitationsassociatedwithexhaledbreathcondensatebiomark-
ers include wide variability, due largely to dilution from wa-
ter vapor during condensation, and low concentrations of the
biomarkers that approach the detection limits of the assays.
These limitations require correction and validation before ex-
haled breath condensate can be reliably used to assess disease
progression in patients with COPD.
Biomarkers in plasma and serum (interleukin [IL]-6, IL-8,
tumor necrosis factor [TNF]-α, ﬁbrinogen, and C-reactive pro-
tein [CRP]) have been studied for their relationship to disease
severity in COPD (11). A recent meta-analysis demonstrated
that neither serum CRP nor serum TNF-α levels are statistically
signiﬁcantly different between healthy subjects and patients at
different COPD stages (11). Data on the relationships between
serum IL-6, IL-8, or ﬁbrinogen and COPD are insufﬁcient and
inconclusive.
In summary, biomarkers obtained from noninvasive collec-
tion methods offer future promise for assessing disease progres-
sion. However, methodological improvements and validation of
the relationship between the biomarkers and disease severity
are required before these markers can be widely adopted as
surrogates of COPD disease progression.
Physiologic indices as surrogate markers for
disease progression in COPD
Subtle physiologic changes that may reﬂect early pathol-
ogy involving peripheral airways occur relatively early in the
course of cigarette smoking (12), but may or may not progress
to clinically signiﬁcant physiologic impairment. Abnormali-
ties in airﬂow (measured by FEV1/FVC) are considered the
physiologic hallmark of COPD by which the disease is de-
ﬁned. It is well known that FEV1 declines with age in all
adults aged 25 years and older; however, the rate of decline
is more rapid in the susceptible smoker than in age-matched
healthy nonsmokers (Figure 3) (13). Just as changes in FEV1
lag behind inﬂammatory and tissue changes, the development
of symptoms is also delayed in comparison with signiﬁcant
decrements in FEV1. In fact, dyspnea may not become evi-
dent until FEV1 has declined to 50–60% of predicted normal
(14). Thereafter, symptoms continue to increase at a rate that
inversely correlates with the subsequent annual change in FEV1
(14).
T h er a t eo fF E V 1 decline is not easily modiﬁed by interven-
tions. It is therefore unclear whether this index is resistant to
change or if the approaches to its modiﬁcation that have been
assessed so far are ineffective. To date, only smoking cessation
unequivocally decreases the rate of FEV1 decline (Figure 4)
(13, 15, 16). Pharmacologic interventions, such as inhaled
corticosteroids (ICS), which are the “gold standard” anti-
inﬂammatory agents for controlling inﬂammation in asthma,
COPD: Journal of Chronic Obstructive Pulmonary Disease June 2009 215Figure 3. Natural history of lung function decline in smokers and nonsmokers (13). British Medical Journal, 1977,1,1645–1648,
reproduced/amended with the permission from the BMJ publishing group.
have failed to alter the rate of FEV1 decline reported in large
trials lasting 3 years or more (15, 17–19). Meta-analyses of
these trials either conﬁrmed the original negative results (20,
21) or identiﬁed a modest but statistically signiﬁcant 7.7 mL
per year improvement in the annual rate of FEV1 decline – the
clinicalsigniﬁcanceofwhichisuncertain(22).Similarly,thean-
tioxidant and mucolytic N-acetylcysteine failed to demonstrate
any impact on the rate of FEV1 decline over 3 years, despite
the anticipated value of this agent given that oxidative stress
is believed to play an important role in COPD pathogenesis
(23).
Only a few trials appear to have shown that pharmacological
intervention alters the rate of FEV1 decline and, thereby high-
light the usefulness of this index in characterizing disease pro-
gression.TheTOwardsaRevolutioninCOPDHealth(TORCH)
trial evaluated the ability of pharmacologic interventions (sal-
meterol/ﬂuticasone combination, ﬂuticasone alone, salmeterol
alone, or placebo) to alter all-cause mortality in approximately
6,000 patients with moderate to very severe COPD over the
course of 3 years (24). The decline in the rate of FEV1 was
not a primary or secondary endpoint and centralized spirom-
etry was not employed; however, post-hoc analysis suggests
Figure 4. Effect of smoking cessation on the decline in lung function (forced respiratory volume in 1 second [FEV1] % predicted) over 5 years
(16). Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS; Lung Health Study investigators/ 2000/ Smoking cessation and lung
function in mild-to-moderate chronic obstructive pulmonary disease/ American Journal of Respiratory and Critical Care Medicine/ 161/381–390.
Ofﬁcial Journal of the American Thoracic Society c  American Thoracic Society.
216 June 2009 COPD: Journal of Chronic Obstructive Pulmonary DiseaseFigure 5. Effect on forced respiratory volume in 1 second (FEV1) of salmeterol and ﬂuticasone propionate administered either alone or in
combination versus placebo over 156 weeks (24). Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J;
TORCH investigators. N Engl J Med 2007;356:775–789. Copyright c  [2007] Massachusetts Medical Society. All rights reserved.
that the rate of decrease in postbronchodilator FEV1 between
6 months and 3 years was slightly but signiﬁcantly less with
salmeterol/ﬂuticasone (39 mL per year; p<0.001) and with
either ﬂuticasone alone or salmeterol alone (both 42 mL per
year; p = 0.003), compared with placebo (55 mL per year)
(Figure 5), with no differences among active treatment arms
(25). Similarly, post-hoc evaluation of FEV1 data from a 1-year
placebo-controlled study of tiotropium in COPD revealed a rate
of decline in predose FEV1 with tiotropium of 12.4 mL per year
(n = 518) compared with a 58 mL per year decline with placebo
(n = 328) (p = 0.005) (Figure 6) (26). A lower and nonsignif-
icant difference in the slope of decline in postbronchodilator
FEV1 was also noted.
Based on these data, a large-scale, multinational trial (Un-
derstanding Potential Long-term Impacts on Function with
Tiotropium [UPLIFT]) of nearly 6,000 patients with moderate-
to-severe COPD (FEV1 <70% of predicted normal after max-
imal bronchodilation) was conducted to determine whether the
long-acting antimuscarinic tiotropium unequivocally decreases
the rate of both pre- and postbronchodilator FEV1 decline in
COPD over a 4-year period in the context of freely prescribed
medications for the treatment of COPD except inhaled anti-
cholinergics (27). The study also examined whether treatment-
related reduction in the rate of FEV1 decline is associated
with concomitant improvements in patient-centered outcomes
(health status, exacerbations, hospitalizations for COPD), as
well as all-cause mortality. The ﬁndings indicated that although
tiotropium was associated with sustained improvements in lung
function, quality of life, and exacerbations during a 4-year pe-
riod, it did not signiﬁcantly reduce the rate of decline in FEV1
(27). These negative ﬁndings need to be interpreted in the
light of the fact that over 70% of UPLIFT participants used
an inhaled corticosteroid and/or long-acting beta-agonist dur-
ing the course of the trial (27), thus making it more difﬁcult
to demonstrate an impact of tiotropium on top of any poten-
tial effect of these concomitant therapeutic agents on decline in
FEV1.
One limitation that affects all of the long-term studies, in-
cluding TORCH and UPLIFT, is that many patients fail to com-
plete the studies, with signiﬁcantly more patients withdraw-
ing from the placebo arms than the active treatment arms (25,
27). It has been observed that the patients who withdraw are
often those who are experiencing more rapid deterioration in
lung function, thereby resulting in the remaining patients es-
sentially representing “healthy survivors” (25, 27). The higher
drop-out rate for individuals in the placebo arm with poorer
lungfunctionpotentiallyminimizesthedifferencesinlungfunc-
tion decline observed between placebo and active interventions
(25, 27).
Patient-centered outcomes as surrogate
markers for disease progression in COPD
Dyspnea
Dyspnea may be considered a potential marker of disease
progression in COPD because of its link with lung function, the
manner in which it changes over time, its utility in predicting
mortality, and its responsiveness to therapy. Dyspnea resulting
from dynamic and resting hyperinﬂation in COPD is now in-
creasingly recognized as a clinically important determinant of
exercise limitation and the ability to perform activities of daily
living (28).
COPD: Journal of Chronic Obstructive Pulmonary Disease June 2009 217Figure 6. Effect of tiotropium on trough forced expiratory volume in 1 second (FEV1) following treatment with tiotropium or administration with
placebo from (A) Days 8–355 and (B) Days 50–344 (26). Reprinted from Pulmonary Pharmacology and Therapeutics, 18, Anzueto A, Tashkin
D, Menjoge S, Kesten S, One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium, 75–81., Copyright
(2005), with permission from Elsevier.
Findings from a range of studies suggest that dyspnea wors-
ens gradually over time in stable COPD. For example, in a
study in which changes in dyspnea were systematically as-
sessed using the UCSD Shortness of Breath Questionnaire in
patients undergoing pulmonary rehabilitation oreducation, dys-
pnea improved or remained stable in most patients, irrespective
of the intervention over the ﬁrst 4 years of the study; however,
dyspnea worsened in both groups over the following 2 years
(29).
In a 1-year placebo-controlled trial with tiotropium in pa-
tients with moderate to very severe COPD, dyspnea (measured
with the Transition Dyspnea Index [TDI]) in the placebo group
improved over the ﬁrst 50 days then worsened (30). In another
study in patients with stable but symptomatic COPD, dyspnea
(measured by TDI) worsened over time and, interestingly, in-
spiratory muscle strength also declined (p<0.001). Multiple
factors, including but not limited to worsening pulmonary me-
chanics resulting from respiratory muscle weakness, may be re-
sponsible for these increases in dyspnea. In addition, increased
dyspnea is reﬂected by deterioration in physical functioning,
which may lead patients to reduce physical activity in order to
minimize discomfort, thereby further impairing exercise toler-
ance and quality of life.
Many long-term trials of pharmacotherapy in COPD have
assessed the impact of interventions on dyspnea. Salme-
terol/ﬂuticasone ﬁxed combination therapy, when compared
with placebo, was found to produce sustained improvements
in TDI score over 6 months that were statistically and clinically
signiﬁcant (+1.7 unit difference) (31) or statistically signiﬁcant
but less than the minimal clinically important difference (+0.8
difference) (32). Similarly, using a Likert scale to grade the
degree of breathlessness, treatment with long-acting β-agonist
(LABA)/ICS combinations has resulted in statistically signiﬁ-
cant reductions in dyspnea (p<0.001) relative to placebo in
1-yeartrials(33–35).Thelong-actinganticholinergictiotropium
produced improvements in dyspnea (measured by the TDI) that
were both statistically and clinically signiﬁcant compared with
placebo (+1.14 difference at 1 year) (30). These improvements
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gressively in the placebo arm over the year.
Inconclusion,dyspneaworsensovertimeinCOPD,isrelated
to physical activity and quality of life, and exhibits sustained
improvement with pharmacologic and nonpharmacologic inter-
ventions; therefore, dyspnea could be considered a surrogate
marker for disease progression in COPD.
Exercise capacity
Exerciseintolerance andexertional dyspneaaremajorsymp-
tomsofCOPDandworsenasthediseaseprogresses.Thepatho-
physiologic basis for the accelerated decline in exercise perfor-
mance is rooted in airﬂow obstruction that results in air trapping
and hyperinﬂation, particularly under the dynamic conditions
of exercise when an increased ventilatory requirement leads to
tachypnea, which shortens the time available for exhalation.
Static and dynamic hyperinﬂation, in turn, lead to exertional
dyspnea and impaired exercise performance due to the asso-
ciated reduction in inspiratory capacity and restricted ability
to expand the tidal volume to meet the increased ventilatory
demands of exercise.
Gas-exchange abnormalities, including hypoxemia and in-
creased wasted ventilation fraction, also contribute to exercise
limitation. An important consequence of the exercise impair-
ment in COPD is adoption of a more sedentary lifestyle and
consequent physical deconditioning that results in lactic acid
accumulationfromprematureanaerobiosisduringexercise.The
latter,inturn,stimulatesventilationandfurtherreducesthetime
for exhalation, thereby leading to a vicious cycle of additional
air trapping, dyspnea, and exercise limitation (36). Ultimately,
this cycle leads to a decline in health-related quality of life
(HRQoL) (Figure 7) (37).
Although it is well known that severe COPD limits exercise
capacity, even mild airﬂow limitation has been shown to reduce
maximal exercise performance. One study demonstrated that
patients with mild airﬂow obstruction (FEV1 74–78% of pre-
dicted) due to COPD had signiﬁcant reductions in peak oxygen
uptake (VO2max) (38). Interestingly, these reductions in VO2max
were related to reductions in tidal volume during maximal ex-
ercise that most likely resulted from a reduced inspiratory ca-
pacity due to dynamic hyperinﬂation, although the latter fac-
tors were not directly measured. Another study of patients with
mild-to-moderate COPD (mean FEV1 72% of predicted nor-
mal)demonstratedsigniﬁcantlyreducedVO2max duringexercise
(69% of predicted) that was associated with the development of
dynamic hyperinﬂation during exercise, despite the presence
of a normal end-expired lung volume at rest (39). These ﬁnd-
ings demonstrate the importance of dynamic hyperinﬂation in
exercise impairment for all COPD severities.
Exercise tolerance shows variable improvement with differ-
ent interventions in COPD, depending both on the nature of the
intervention and on the test used to measure exercise perfor-
mance. The 6-minute walking distance (6MWD) can be con-
founded by poor repeatability and learning effects, but exercise
endurance time during a constant work rate submaximal exer-
cise test has been shown to be a reliable and repeatable measure
of exercise endurance that is responsive to changes with bron-
chodilator therapy in COPD (40, 41). Pulmonary rehabilitation
generally improves exercise endurance but has little effect on
maximalexerciseperformance(42).Bronchodilatortherapyhas
only infrequently been shown to improve the 6MWD but has
more often been observed to improve submaximal exercise en-
durance time (43–45).
Oga and colleagues (46) compared the sensitivity of 3 differ-
ent exercise tests—6MWD, incremental cycloergometry (ICE),
Figure 7. Air trapping links pathophysiology and patient-centered outcomes in COPD (37). Reprinted from American Journal of Medicine,
119, Cooper CB, The connection between chronic obstructive pulmonary disease symptoms and hyperinﬂation and its impact on exercise and
function, S21–S31., Copyright (2006), with permission from Elsevier.
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bronchodilator therapy. While all three tests revealed a statis-
tically signiﬁcant improvement in exercise performance after
administration of the bronchodilator (compared with placebo),
the percent improvement was substantially greater when exer-
cise performance was measured by endurance time (19%) than
by VO2max (3%), maximal minute ventilation (6%), maximal
work rate (4%), or 6MWD (1%). Therefore, the endurance
test appears to be the most sensitive method for assessing
the beneﬁts of an intervention on exercise performance in
COPD.
Exercise capacity also appears to be sensitive to therapeutic
intervention. Tiotropium administered daily for 6 weeks pro-
gressively improved endurance time compared with placebo
during a constant work rate exercise test (43, 44). These ben-
eﬁcial effects on exercise performance were paralleled by im-
provements in inspiratory capacity, tidal volume, minute ven-
tilation, and dyspnea. Salmeterol also led to improvements in
several measures of exercise performance during both incre-
mental and constant-load exercise after 2 weeks of treatment
(45). The combination of pulmonary rehabilitation and treat-
ment with tiotropium has been shown to have additive effects in
improving exercise tolerance in COPD.
These improvements are presumably related to improved
muscleconditioningresultingfromthepulmonaryrehabilitation
and reduced airﬂow limitation and hyperinﬂation concomitant
with bronchodilator treatment (47). The beneﬁts of combined
pulmonary rehabilitation and tiotropium in improving exercise
tolerance were accompanied by clinically meaningful improve-
ments in dyspnea and quality of life compared with pulmonary
rehabilitation alone. Strategies that lead to substantial improve-
ments in exercise tolerance or reduce its rate of decline, such
as long-acting bronchodilator treatment in combination with
pulmonary rehabilitation, could therefore be considered to be
disease-modifying.
Health-related quality of life
Placebo arms of randomized controlled trials as well as co-
hort studies demonstrate that HRQoL declines with time in
patients with COPD (48, 49). Numerous studies have demon-
strated correlations between decline in HRQoL and other as-
pects of COPD, such as exacerbations, FEV1 decline, and mor-
tality. For example, data from the ISOLDE (Inhaled Steroids
in Obstructive Lung Disease) trial demonstrated correlations
between exacerbation rate and HRQoL (50). Frequent exacer-
bations (>1.65 per year) were independently associated with a
worse baseline St George’s Respiratory Questionnaire (SGRQ)
score and a more rapid rate of deterioration in HRQoL. Simi-
larly,inthesametrial,progressivechangeinFEV1 wasobserved
to correlate with change in SGRQ score (49). Poor HRQoL has
also been shown to predict mortality (51).
The rate of change in HRQoL can be altered by therapeu-
tic interventions. For example, SGRQ total scores in patients
with moderate to severe COPD treated with ﬂuticasone propi-
Figure 8. Slope of deterioration in health status calculated using
estimates from a random coefﬁcients hierarchical model for pa-
tients treated with ﬂuticasone proprionate or placebo over 3 years
(49). Spencer S, Calverley PM, Sherwood Burge P, Jones PW;
ISOLDE Study Group/ 2001/ Health status deterioration in patients
with chronic obstructive pulmonary disease/ American Journal of
Respiratory and Critical Care Medicine/ 163/ 122–128. Ofﬁcial
Journal of the American Thoracic Society c  American Thoracic
Society.
onate 500 µg twice daily took longer to deteriorate by 4 points
(the minimum clinically important difference) than patients
treated with placebo (24 months versus 15 months) (Figure 8)
(49). Similarly, over a period of 1 year, patients with stable
COPD who were treated with tiotropium 18 µg showed sus-
tained improvements in their HRQoL scores whilst patients re-
ceiving placebo showed the expected decline in health status
(30). Combination treatment with salmeterol and ﬂuticasone
also produced a clinically signiﬁcant improvement in HRQoL
andlungfunctioncomparedwithplaceboinpatientswithCOPD
(Figure 9) (24).
These results must be considered while bearing in mind the
effects of COPD exacerbations on HRQoL. It is well known
that HRQoL deteriorates signiﬁcantly following an exacerba-
tion (52). Thus, the extent of improvement in HRQoL seen for
interventions that reduce the rate of exacerbations will differ
from that of interventions that only improve other aspects of
the disease such as dyspnea or FEV1. In addition, results from
placebo-controlled trials are likely to be inﬂuenced by differ-
ential drop-out rates between groups receiving active treatment
and those on placebo. Analysis of HRQoL in the ISOLDE study
revealed that the deterioration in SGRQ total, symptom, and
impact scores for placebo-treated patients who withdrew was
signiﬁcantly greater than either that of placebo completers or
the patients treated with ﬂuticasone (53).
When considering whether changes in HRQoL are an
appropriate means by which to monitor disease progression,
it is important to recognize that HRQoL measures reﬂect the
effects of the disease, rather than providing a measure of the
disease itself. The relationship between poor HRQoL and
other disease aspects, e.g., increased mortality, results from the
fact that both reﬂect underlying disease activity. One of the
220 June 2009 COPD: Journal of Chronic Obstructive Pulmonary DiseaseFigure 9. Change in Health-related Quality of Life (HRQoL) over 156 weeks following treatment with placebo, ﬂuticasone proprionate, salmeterol
or ﬂuticasone proprionate and salmeterol administered in combination (24). Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones
PW, Yates JC, Vestbo J; TORCH investigators. N Engl J Med 2007;356:775–789. Copyright c  [2007] Massachusetts Medical Society. All rights
reserved.
advantages of considering changes in HRQoL as a surrogate
marker for disease progression is that it can be monitored
relatively easily using disease-speciﬁc questionnaires.
Exacerbations
Exacerbations are primarily a feature of severe-to-very-
severe COPD, although they also appear in the earlier stages
of the disease. Frequent exacerbations are associated with more
rapid decline in FEV1, impaired functional status and HRQoL,
worse survival, and increased costs and hospitalizations
(50, 54–56).
A signiﬁcant body of evidence supports the use of LABAs,
long-acting muscarinic antagonists, and ICS to reduce the rate
of exacerbations in patients with moderate-to-severe COPD
(34, 35, 57). Furthermore, combining these agents may pro-
vide greater beneﬁts than use of each component alone. For
example, recent data from the TORCH study suggest that the
combination of a LABA and an ICS reduces the rate of ex-
acerbations to a signiﬁcantly greater extent than either com-
ponent administered alone (p<0.002 for salmeterol and ﬂu-
ticasone versus salmeterol; p<0.02 for salmeterol and ﬂu-
ticasone versus ﬂuticasone) (24). Reducing or preventing ex-
acerbations is an important component of disease modiﬁca-
tion in COPD; however, the low frequency of exacerbations
in patients with mild COPD may limit the utility of this out-
come as a measure of progression during the early stages of the
disease.
Mortality
Death is the ultimate consequence of disease progression
and thus reduced mortality and improved survival describe an
impact on disease progression. Numerous factors are reported
to inﬂuence mortality in COPD including FEV1 (58), dyspnea
(59), disease duration (60), carbon dioxide and oxygen arterial
tensions (56), cardiac status (54), body mass index (61), serum
albumin level (62), functional status (63), exercise limitation
(63,64)andco-morbidities(55).Thecorrelationsbetweenthese
cofactors and long-term mortality are variable.
Interventions that impact on mortality most probably do
so via improvements in aspects of lung function and patient-
centeredoutcomes,althoughtheremaybeother,asyetunknown
ways in which interventions affect this endpoint (Figure 10).
Smoking cessation has beneﬁcial effects on subsequent
Figure 10. Direct and indirect ways by which interventions impact
on mortality.
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mortality after 14.5 years (65). Long-term home oxygen ther-
apy has been shown to reduce mortality in patients with persis-
tent hypoxemia, as has lung volume reduction therapy in highly
selected patients with emphysema (66–68). In addition, a re-
cent meta-analysis showed that pulmonary rehabilitation after
a COPD exacerbation reduced the risk of mortality (pooled rel-
ative risk 0.45 [95% conﬁdence interval (CI) 0.22–0.91]) (69).
Further research is required to deﬁne the long-term effects of
these interventions.
The effect of a pharmacologic intervention on mortality was
recently investigated in the TORCH study. In this study, pa-
tientsreceivedeithersalmeterol/ﬂuticasoneincombination,sal-
meterol alone, ﬂuticasone alone, or placebo, for 3 years (24).
Of 6,112 patients in the efﬁcacy population, 875 died over the
3-yearstudy.Thehazardratioforall-causemortalityinthecom-
bination therapy group compared with the placebo group was
0.825 (95% CI 0.681–1.002; p = 0.052), corresponding to a
reduction in the absolute risk of death of 2.6% (17.5% relative
reduction), which approached statistical signiﬁcance. Further
factorial analysis indicated that the effect on mortality of the
combination therapy appeared to be entirely due to salmeterol,
and that the effect was highly signiﬁcant (p = 0.004) (70).
This underscores the important role that airﬂow limitation
plays indisease progressionand, consequently, theneed foritto
be managed. Despite the lack of a statistically signiﬁcant reduc-
tion in mortality, combination therapy did result in signiﬁcantly
fewer exacerbations and improved HRQoL and lung function
compared with placebo. Clinical ﬁndings from the study, how-
ever, suggest that monotherapy with corticosteroids should not
be recommended, but that LABAs used alone or in combination
may provide beneﬁt. It is clear from the ﬁndings of the TORCH
study that further investigation is required into the effect on
mortality of pharmacotherapy in COPD.
While UPLIFT focused primarily on the rate of decline in
FEV1 as a primary endpoint, mortality was a key prespeciﬁed
secondary endpoint. As in TORCH, vital status was ascertained
in nearly all patients over the protocol-deﬁned treatment period,
permitting an intention-to-treat analysis of the impact of the
study medication on mortality. The hazard ratio for all-cause
mortality over the 1,440-day protocol-deﬁned duration of the
study (vital status known in 95% of all randomized subjects)
was 0.87 (95% CI 0.76–0.99; p = 0.034), while that over this
sametimeperiodplus30days(1470days),asprespeciﬁedinthe
analysisplan,(vitalstatusknowninonly75%ofallsubjectsover
the latter time period) was 0.89 (95% CI 0.79–1.02; p = 0.086)
(27).
Thus, both of the recent long-term trials of pharmacother-
apy in COPD (TORCH and UPLIFT) revealed an impact on
mortality that came tantalizingly close to achieving statistical
signiﬁcance. The mechanism(s) of this effect need to be further
explored but could involve several factors, including reductions
in exacerbations and in respiratory failure, as well as improve-
ments in ventilatory mechanics, including a reduction in hyper-
inﬂation, that may have indirect cardiac beneﬁts through, for
example, a decrease in cardiac afterload.
Since mortality is an end result of COPD, it can be a useful
endpoint to deﬁne an impact on disease progression within a
population receiving a study medication. However, mortality is
not suitable for assessment of disease progression in individual
patients. It is further complicated by co-morbid conditions as-
sociated with COPD that can involve organ system dysfunction
sufﬁcient to contribute to mortality independently or addition-
ally, but not exclusively due to COPD. Therefore, mortality is
appropriate to deﬁne the end result of disease progression; how-
ever, it is not appropriate for describing disease progression in
individual patients or in clinical practice.
CONCLUSIONS
The proposed working deﬁnition of disease modiﬁcation
was:
an improvement in, or stabilization of, structural or functional
parameters as a result of reduction in the rate of progression of these
parameters which occurs whilst an intervention is applied and may
persist even if the intervention is withdrawn.
In many cases the structural changes cannot be monitored di-
rectly and surrogate markers of improvements must be used.
These remain to be fully delineated, but include physiologi-
cal parameters, such as FEV1, as well as patient-centered out-
comes,suchasexacerbationrates,breathlessness,exercisetoler-
ance,andHRQoL.Animportantunansweredquestionconcerns
the minimum duration of the structural/functional improvement
that is required for an intervention to be considered disease-
modifying. Longitudinal data are needed to reﬁne the deﬁnition
of disease modiﬁcation in COPD.
FEV1 decline retains an important role in monitoring the
course of COPD. However, given the interdependence between
physiological and patient-centered outcomes in COPD, treat-
ments aimed at preventing disease progression should ideally
demonstrate improvements across multiple outcomes. Accord-
ing to the proposed deﬁnition, smoking cessation and lung
volume reduction surgery should be considered to be disease-
modifying interventions. A pharmacologic intervention may be
considered disease-modifying if it provides consistent and sus-
tained improvements in structural (e.g., reduction in exacerba-
tions as surrogate marker) and functional (e.g., improvement in
FEV1 and exercise tolerance as surrogate marker) parameters.
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